CRISPR pioneer Feng Zhang co-founds a 'limitless' biotech upstart with big plans for speeding new drug development
One of the key scientific players involved in the emergence of the incredibly buzzy gene editing tech CRISPR/Cas9 is backing a biotech startup called Arbor Biotechnologies in Cambridge, MA, which just unveiled what it believes is a new, more versatile CRISPR tech.
In a paper published today in Molecular Cell, two former members of Feng Zhang’s lab — David Scott and Winston Yan — outlined their discovery of an enzyme called Cas13d, which they say is considerably smaller and better than the rest of the Cas13 family of enzymes, giving it greater potential in RNA surgery. And their paper was published on the same day as a separate study out of Salk which centered on the exact same enzyme.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
